Program
400mg of TQB3909 tablets
A development code. Also written as “600mg of TQB3909 tablets”.
In Sino Biopharmaceutical’s pipeline, BCL-2抑制剂
. Its studies are mostly in Lymphoma, Mantle-Cell, led by Sino Biopharmaceutical.
Furthest: phase 2, since Oct 24, 20231 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 10 open or running | phase 2since Oct 24, 2023 | Oct 24, 2023 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB3909
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 24, 2023First study: phase 2 study in Lymphoma, Mantle-CellFirst studyNCT06106841 · 19 enrolled · China
TargetBeta
“BCL-2抑制剂”the company's pipeline, read by Claude · source
Other programs on BCL2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| venetoclaxrule | AbbVie | phase 4 | 83 |
| Bcl-2 Inhibitor TQB3909 | Sino Biopharmaceutical | phase 3 | 8 |
| lacutoclaxrule | Lupeng Pharmaceutical | phase 2 | 4 |
| surzetoclax | AbbVie | phase 2 | 3 |
| surzetoclax | AbbVie | phase 1 | 2 |
| FXS0683 | Fosun Pharma | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06106841Lymphoma, Mantle-Cell · China | 2 | Terminated | Oct 16, 2024 | 19 |
How it is read
Names in the registry
- “400mg of TQB3909 tablets”, 1 entry
- “600mg of TQB3909 tablets”, 1 entry
Codes read as this program: TQB3909.
Conditions, from the studies’ own filings
- Lymphoma, Mantle-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.